Leading Market and Competitive Intelligence Company within Lifesciences and Healthcare Segment in India
Home
About Us
Segments We Cater
Awards & Recognition
Publications
Cognitrex in News
Customize Services
Market Research and Consulting
Secondary Research
Government Business Facilitation
Medical Event Management
Licensing Opportunity
Healthcare Technologies
Digital marketing
Syndicated Services
Fertility Tracker
Medical Equipment Tracker
Reports
Contact
Cognitrex Institute
HR Consulting
Blog
Home
About Us
Segments We Cater
Awards & Recognition
Publications
Cognitrex in News
Customize Services
Market Research and Consulting
Secondary Research
Government Business Facilitation
Medical Event Management
Licensing Opportunity
Healthcare Technologies
Digital marketing
Syndicated Services
Fertility Tracker
Medical Equipment Tracker
Reports
Contact
Cognitrex Institute
HR Consulting
Blog
Blog Grid
Home
Blog Grid
wtadmin
July 28, 2021
BDR Pharma launches the first generic RUCAPARIB to treat advanced ovarian and prostate cancers in India
wtadmin
July 28, 2021
Lupin receives $50 million from Boehringer Ingelheim for achievement of key milestones
wtadmin
July 28, 2021
Novartis announces positive data from phase II ELARA trial of Kymriah in patients with relapsed or refractory follicular lymphoma
wtadmin
July 28, 2021
Bristol Myers Squibb gets European approval for Opdivo plus Yervoy to treat unresectable malignant pleural mesothelioma
wtadmin
July 28, 2021
Zydus Cadila gets tentative USFDA nod to market lung cancer treatment drug
wtadmin
July 28, 2021
Roche withdraws Tecentriq for bladder cancer; pullback comes amid FDA review
wtadmin
July 28, 2021
Alkem Laboratories ties with Tata Memorial Hospital to establish cancer care facility in Bihar
wtadmin
July 28, 2021
Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma
wtadmin
July 28, 2021
FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
wtadmin
July 28, 2021
US FDA grants priority review status for Merck & Eisai’s Keytruda plus Lenvima applications for advanced RCC and advanced endometrial carcinoma
1
2
Close